Bacon K B, Schall T J, Dairaghi D J
Department of Immunobiology, DNAX Research Institute, Palo Alto, CA 94304, USA.
J Immunol. 1998 Feb 15;160(4):1894-900.
The chemokine RANTES is a potent agonist of T cell activation. In an investigation of signal-transduction events activated by this chemokine, we have shown that RANTES stimulates dose-dependent phospholipase D (PLD) activity in Jurkat cells. Equilibrium-binding analyses using 125I-labeled RANTES indicated the presence of a receptor for RANTES on these cells, which has a Kd of 0.1 nM, is expressed at approximately 600 sites per cell, and a binding specificity that was not comparable with that of any of the known chemokine receptors, since 125I-labeled RANTES was displaced by macrophage-inflammatory protein-1 beta (but not macrophage-inflammatory protein-1 alpha), monocyte-chemotactic protein-1 (MCP-1), MCP-3, MCP-4, and eotaxin. RANTES-induced PLD activation was augmented by GTP gamma S, but not GDP beta S, and inhibited by the protein kinase C inhibitor bisindolylmaleimide, as well as the fungal metabolite brefeldin A, and C3 exoenzyme (Clostridium botulinum), implicating the activation of RhoA. RANTES also induced GTP-GDP exchange of immunoprecipitated RhoA. RANTES-stimulated PLD activity was dependent on an ADP-ribosylation factor(s), as assessed by inhibition studies using a synthetic inhibitory peptide of the N-terminal 16 amino acids of ADP-ribosylation factor 1. These studies indicate the potential existence of a novel receptor-mediated mechanism for activation of T cells by the chemokine RANTES.
趋化因子RANTES是T细胞活化的强效激动剂。在对该趋化因子激活的信号转导事件的研究中,我们发现RANTES可刺激Jurkat细胞中剂量依赖性的磷脂酶D(PLD)活性。使用125I标记的RANTES进行的平衡结合分析表明,这些细胞上存在RANTES受体,其解离常数(Kd)为0.1 nM,每个细胞约有600个表达位点,且结合特异性与任何已知趋化因子受体均不相同,因为125I标记的RANTES可被巨噬细胞炎性蛋白-1β(而非巨噬细胞炎性蛋白-1α)、单核细胞趋化蛋白-1(MCP-1)、MCP-3、MCP-4和嗜酸性粒细胞趋化因子取代。RANTES诱导的PLD激活可被GTPγS增强,但不能被GDPβS增强,且受到蛋白激酶C抑制剂双吲哚马来酰胺、真菌代谢产物布雷菲德菌素A和C3外切酶(肉毒梭菌)的抑制,这表明RhoA被激活。RANTES还诱导免疫沉淀的RhoA发生GTP-GDP交换。通过使用ADP-核糖基化因子1 N端16个氨基酸的合成抑制肽进行抑制研究评估,RANTES刺激的PLD活性依赖于一种ADP-核糖基化因子。这些研究表明,趋化因子RANTES可能存在一种新型的受体介导的T细胞激活机制。